Excellent cutaneous tolerability profile

Demonstrated cutaneous
tolerability profile

Mean local signs and symptoms graded from 0 (none) to 3 (severe) at baseline through 12 weeks

Mean cutaneous tolerability scores reviewed with subject at study visit (average over period since prior visit); combined results from two Phase 3 clinical trials (n=773):

  • Low rate of stinging, itching, and burning (mean scores <1, where 1=mild).
  • At week 12, erythema and scaling were reported by 15% and 8% of patients, respectively; itching, burning and stinging were reported by 6%, 2% and 1%, respectively.
  • Most local skin reactions increased and peaked around Week 4 and continually decreased over time, reaching near-baseline levels by Week 12.
  • Patients should be advised to avoid contact with the eyes or mucous membranes.

Very low discontinuation rate

  • No patients on Acanya discontinued treatment due to erythema, scaling, burning, stinging, or itching.
  • 91% of patients treated with Acanya completed the 12-week studies.
    • Reasons for discontinuation included: patient request, nonadherence to protocol, lost to follow-up, lack of efficacy/worsening of condition, pregnancy, AEs, and other.

NEXT: Once-daily dosing

Safety Considerations

Acanya Gel may cause irritation such as erythema, scaling, itching, or burning, especially when used in combination with other topical acne therapies.

Acanya Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic associated colitis. Clindamycin taken orally or through IV may result in severe colitis, which may result in death.

Anaphylaxis as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately.